Partial Gastric Resection for Symptomatic Anemia following Diagnosis of Merkel Cell Carcinoma (MCC) of the Skin with Gastric Metastasis

Zachary Eagle1, Francis Essien2,3, George Shahin3, Amia Jones4, John McKee4, Camille Elkins5 and Wassem Juakiem6

1Department of Internal Medicine, Keesler Medical Center, Keesler Air Force Base, Biloxi, MS, USA. 2Department of Internal Medicine, David Grant Medical Center, Travis Air Force Base, Fairfield, CA, USA. 3Division of Hematology and Oncology, Department of Internal Medicine, Keesler Medical Center, Keesler Air Force Base, Biloxi, MS, USA. 4Division of Gastroenterology, Department of Internal Medicine, Singing River Hospital System, Biloxi, MS, USA. 5Department of Pathology, Singing River Hospital System, Biloxi, MS, USA. 6Division of Gastroenterology, Department of Internal Medicine, Keesler Medical Center, Keesler Air Force Base, Biloxi, MS, USA.

ABSTRACT: Merkel Cell Carcinoma (MCC) is a rare dermatologic malignancy with significant morbidity and mortality associated with metastatic disease. In this case, we discuss an extremely rare presentation of MCC with metastasis to the stomach in a patient that presented with profound anemia. Unfortunately, mortality following diagnosis of MCC with gastric metastasis approaches 67% at 4 months based on available published reports. Due to its rarity and high rate of mortality, there is a lack of available research and literature to help guide treatment of this rare presentation of MCC. This case report presents a positive outcome associated with a partial gastrectomy for the treatment of symptomatic MCC with gastric metastasis and continued survival with persistently stable hemoglobin at 12 months.

KEY CLINICAL MESSAGE:
Anemia may be a significant cause of the morbidity and mortality associated with MCC with gastric metastasis. Our case demonstrates a positive outcome associated with partial gastric resection and presents a possible treatment option for this rare disease process.

KEYWORDS: Carcinoma, Merkel cell, immunotherapy, anemia, refractory

Introduction
Merkel Cell Carcinoma (MCC) is a rare, highly aggressive cutaneous dermatologic malignancy with an incidence of 0.7 per 100,000 persons that is typically seen in older, fair skinned adults.1 Development of MCC is attributed to multiple risk factors such as Merkel Cell Polyomavirus, ultraviolet (UV) radiation, and immunosuppression.2 MCC has a high propensity for metastasis with the most common sites being lymph nodes, skin, lung, liver, bone, and brain.1,2 Though the malignancy is uncommon, recorded metastasis to the stomach is exceedingly rare with only 13 identified cases reported in the literature.3-14 In this case report, we discuss the outcomes of a partial gastrectomy for the treatment of symptomatic MCC with gastric metastasis.

Case Description
An 84-year-old African American male with recently diagnosed metastatic MCC presented to the emergency room with progressively worsening shortness of breath, fatigue, and melena. He had been initiated on immunotherapy treatment with pembrolizumab. Patient denied any recent history of peptic ulcer disease, anticoagulation therapy, or recent non-steroidal anti-inflammatory drug (NSAID) use. On physical exam, the abdomen was non-tender without guarding or rigidity, however rectal exam showed maroon colored stools. Laboratory analysis was notable for a hemoglobin of 4.8 g/dL. Aggressive intravenous fluid resuscitation, red blood cell transfusions, and proton pump inhibitor therapy was immediately initiated. Gastroenterology was consulted and performed an upper endoscopy which revealed a malignant appearing 3-cm ulcerated gastric nodule with stigmata of recent bleeding (Figure 1). Gastric biopsy results showed focally ulcerated MCC. A partial gastrectomy was performed during hospitalization with resolution of the patient’s bleeding. Both biopsy and resection of the stomach mass showed gastric mucosa with a submucosal cellular proliferation arranged in sheets and expansile nests. Tumor cells showed increased nuclear size, scant cytoplasm, fine chromatin, and indistinct nucleoli. Mitoses were frequent (up to 4/mm²) and single cell necrosis was conspicuous in a background of crush artifact. No evidence of divergent differentiation or other elements was identified. Immunohistochemical staining was performed with appropriately staining controls. Tumor cells were positive for pancytokeratin, NSE, chromogranin, synaptofysin, and...
Figure 1. Endoscopic appearance of MCC with gastric metastasis.

Figure 2. Chromogranin stain, 600× magnification of gastric mucosal biopsy.

Figure 3. Synaptophysin stain, 600× magnification of gastric mucosal biopsy.

Figure 4. CK20 stain, 600× magnification, Gastric mucosal biopsy depicting tumor cell positivity in the characteristic paranuclear dot-like pattern.

Figure 5. Hematoxylin and Eosin stain, 400× magnification of gastric wedge resection depicting gastric mucosa with tumor cells in the lamina propria.
CK20 (classic perinuclear dot-like pattern) (Figures 2, 3, and 4). The Ki67 proliferation index was increased (80%). TTF-1 and CD45 were negative, arguing against metastatic small cell carcinoma of the lung and lymphoma, respectively. These morphologic and immunohistochemical features along with the patient’s history of MCC were consistent with a diagnosis of metastatic MCC (Figure 5). One year after resection, our patient remains asymptomatic with stable hemoglobin.

Discussion

Though rare, the incidence of MCC has tripled over the last decade and mortality from advanced MCC has risen by over 300%.13,16 The exact reason for the increasing incidence and mortality is not well understood at this time but may be due to improved understanding of the pathogenesis, aging populations, increased immunocompromised patients, and refined diagnostic tools.14

The diagnosis of MCC begins with high clinical suspicion. The AEIOU acronym was developed by Heath et al and summarizes the common clinical findings: asymptomatic, expanding rapidly, immunosuppressed, older age, and UV exposure.17 The gold standard for diagnosis is biopsy as MCC must be differentiated from other neuroendocrine tumors, melanoma, cutaneous lymphoma, and small cell lung carcinoma.18

Immunohistochemical staining is necessary to demonstrate positivity for broad spectrum keratins (AE1/3), neuroendocrine markers (chromogranin, synaptophysin, neuron specific enolase, CD56), and CK20 positivity in a classic dot-like paranuclear pattern.16,19 Available literature regarding MCC tumor cells immunoprofiles notes the use of maspin as a possible marker to assist the diagnosis of MCC, particularly in relation to sun exposure.19 Though this stain was not readily available at our institution, its positivity appears to be suggestive of MCC and could be used as an additional marker when available. Negative staining with cd57, pax5, tdt, CK7, ttf-1, s-100, and LCA help rule out metastasis form other sites (small cell lung carcinoma), lymphoma, and melanoma.18-20

According to the National Comprehensive Cancer Network, immunotherapy with PD-1/PD-L1 blockade is typically used for metastatic MCC due to improved side effect profile when compared with chemotherapy or surgery.21,22 Given the rarity of metastasis of MCC to the gastric mucosa, no clear treatment guidelines have been established. Gastrointestinal bleeding appears to be the most common presentation of MCC with gastric metastasis.13-14 Mortality rates range from 24 months with an average mortality rate of 67% at 4 months following diagnosis of gastric metastasis.13-14 Of the 13 case reports identified, 2 patients underwent aggressive surgical intervention in addition to traditional pharmacologic regimens. One prior study reports the use of a Billroth II resection with subsequent survival at 24 months.14 Partial gastric resection was pursued in our patient as he was already on immunotherapy and was high risk for recurrent symptomatic anemia. Over 12 months after resection, the patient had no recurrent bleeding events with a stable hemoglobin of 13.9 g/dL.

Anemia may play an important role in the morbidity and mortality associated with MCC with gastric metastasis. Our patient demonstrated hematologic stability and symptomatic improvement following partial gastric resection. However, given the rarity and early mortality associated with this presentation, further research into the efficacy of partial gastric resection may prove difficult. Our case report demonstrates a positive outcome associated with partial gastric resection and presents a possible treatment option for this rare disease process.

Author Contributions

Zachary R Eagle, Francis Essien, Wassem Juakiem: Study conception and design. Zachary R Eagle, Amia Jones, John McKee, Wassem Juakiem: Data collection. Zachary R Eagle, Wassem Juakiem: Analysis and interpretation of results. Zachary R Eagle, Francis Essien, George Shahin, Wassem Juakiem: Draft manuscript preparation. All authors discussed the results and contributed to the final manuscript. Data sharing is not applicable to this article as no new data were created or analyzed in this study.

ORCID iD

Francis Essien https://orcid.org/0000-0001-5337-2463

REFERENCES

1. Agelli M, Clegg LX. Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol. 2003;49:832-841.
2. Albores-Saavedra J, Batich K, Chable-Montero F, Sagy N, Schwartz AM, Henson DE. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol. 2010;37:20-27.
3. Trivedi D, Collins V, Roberts E, et al. Perforated gastric metastasis of Merkel cell carcinoma: case report and review of the literature. Hum Pathol. 2017;8:20-23.
4. Parikh PM, Sano S, Ganjipetiti V, et al. Gastric metastasis of Merkel cell carcinoma, a rare cause of gastrointestinal bleeding: case report and review of the literature. J Gastrointestin Oncol. 2014;5:68-72.
5. Syal NG, Dang S, Rose J, Chen C, Adulì F. Gastric metastasis of Merkel cell carcinoma—an uncommon complication of a rare neoplasm. J Ark Med Soc. 2012;109:134-136.
6. Idoowu MO, Contos M, Gill S, Powers C. Merkel cell carcinoma: a report of gastrointestinal metastasis and review of the literature. Arch Pathol Lab Med. 2003;127:367-369.
7. Ho ZJ, Schuster JA, Kudelka AP, Huston TL. Merkel cell carcinoma with gastric metastasis and review of literature. J Cutan Med Surg. 2016;20:255-258.
8. Tarantola TI, Vallow LA, Halyard MY, et al. Prognostic factors in Merkel cell carcinoma: analysis of 240 cases. J Am Acad Dermatol. 2013;68:425-432.
9. Li M, Liu C. Cytokeratin 20 confirms Merkel cell metastasis to stomach. Appl Immunohistochem Mol Morphol. 2004;12:346-349.
10. Canales L1, Parker A, Kadakia S. Upper gastrointestinal bleeding from Merkel cell carcinoma. Am J Gastroenterol. 1992;87:1464-1466.
11. Krasagakis K, Almond-Roessler B, Zouboulis CC, et al. Merkel cell carcinoma: report of ten cases with emphasis on clinical course, treatment, and in vitro drug sensitivity. J Am Acad Dermatol. 1997;36:727-732.
12. Cubieith J, Salgado M, Rui M, et al. (Gastric metastasis due to Merkel cell carcinoma: a rare case of gastric bleeding. J. Rev Esp Enferm Dig. 2004;96:150-151.
13. Wolov K, Tully O, Mercogliano G. Gastric metastasis of Merkel cell carcinoma. *Clin Gastroenterol Hepatol*. 2009;7:A26.
14. Rosa F, Pacelli F, Papa V, et al. Merkel cell carcinoma metastatic to the stomach. *ANZ J Surg*. 2010;80:100-101.
15. Schadendorf D, Lebbé C, zur Hausen A, et al. Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs. *Eur J Cancer*. 2017;71:53-69.
16. Fitzgerald TL, Dennis S, Kachare SD, Vohra NA, Wong IH, Zervos EE. Dramatic increase in the incidence and mortality from Merkel cell carcinoma in the United States. *Am Surg*. 2015;81:802-806.
17. Heath M, Jaimes N, Lemos B, et al. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEHOU features. *J Am Acad Dermatol*. 2008;58:375-381.
18. Bichakjian CK, Lowe L, Lao CD, et al. Merkel cell carcinoma: critical review with guidelines for multidisciplinary management. *Cancer*. 2007;110:1-12.
19. Turdean SG, Gurzu S, Jung I, Negoe RM, Sala D. Unexpected maspin immunoreactivity in Merkel cell carcinoma. *Diagn Pathol*. 2015;10:206.
20. Bobos M, Hytiroglou P, Kostopoulos I, Karkavelas G, Papadimitriou CS. Immunohistochemical distinction between Merkel cell carcinoma and small cell carcinoma of the lung. *Am J Dermatopathol*. 2006;28:99-104.
21. NCCN Guidelines version 1. 2021. Merkel cell Carcinoma. Accessed July 11, 2021. http://www.nccn.org/professionals/physician_gls/pdf/mcc.pdf
22. Nghiem P, Bhatia S, Lipson EJ, et al. Durable tumor regression and overall survival in patients with advanced merkel cell carcinoma receiving pembrolizumab as first-line therapy. *J Clin Oncol*. 2019;37:693-702.